Breaking News Instant updates and real-time market news.

AST

Asterias

$1.60

0.05 (3.23%)

16:48
08/09/18
08/09
16:48
08/09/18
16:48

Asterias reports Q2 EPS (13c), consensus (10c)

Cash, cash equivalents, and available-for-sale securities totaled $14.8million as of June 30, 2018. The Company has successfully lowered its quarterly cash burn during the first half of 2018 and anticipates similar low quarterly cash utilization for the remainder of 2018.

  • 09

    Aug

  • 04

    Sep

AST Asterias
$1.60

0.05 (3.23%)

02/22/18
RILY
02/22/18
INITIATION
Target $6
RILY
Buy
Asterias initiated with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico started Asterias Biotherapeutics with a Buy rating and $6 price target. The analyst believes the company has shown "promising signs of efficacy" in spinal cord and cancer.
02/22/18
02/22/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Loxo Oncology (LOXO) initiated with an Outperform at Oppenheimer. 2. Asterias (AST) initiated with a Buy at B. Riley FBR. 3. Viveve (VIVE) initiated with a Buy at Empire. 4. Panhandle Oil & Gas (PHX) initiated with a Buy at Roth Capital. 5. Aduro Biotech (ADRO) initiated with an Overweight at Cantor Fitzgerald. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.